Ichor CEO delivers workshop and Lysoclear update at annual LEAF conference

NEW YORK, NY: The second annual Life Extension Advocacy Foundation (LEAF) Ending Age Related Diseases Conference was held in New York City July 11-12^th. This conference brought together many of the top minds in the biotechnology rejuvenation field, including Dr. Kelsey Moody, CEO at Ichor Therapeutics, Inc. Dr. Moody also held a workshop prior to the conference, on July 10^th.

The workshop was held in the Cooper Union Square as two 1.5-hour sessions. Here, he discussed some of the main elements to developing and maintaining a successful biotechnology company, specifically in the aging field. Dr. Moody has grown Ichor from a living room laboratory into a thriving business with multiple portfolio companies since its creation in 2013. At this workshop, essential tips and key information were shared with attendees regarding how to start and maintain a prosperous business in this industry. This included mechanisms necessary to grow a profitable company and strategic methods used to create a productive work environment necessary to generate ideal results. As the aging population continues to grow exponentially, new medications and treatments will be sought out at unimaginable rates. The aging field is one of the fastest growing in today’s society. Biotechnology companies focused on aging and age-related diseases understand the necessity of taking this research to practical, clinical usage.

For two days following the workshop, a myriad of the top researchers in the aging field presented at LEAF’s Ending Age Related Diseases. Dr. Huda Suliman, president of Ichor’s contract research arm, Icaria Life Sciences, Inc., presented the first day of the conference. She discussed considerations in developing a translational pipeline with a focus on nuances specific to the aging space. On the second day of the conference, Dr. Kelsey Moody presented a research update on Lysoclear’s enzyme augmentation therapy (EAT) for macular degeneration. This research may lead to new treatments for the disease, which affects more than 200,000 US citizens per year and is the leading cause of vision loss in people over 60.

LEAF’s Ending Age Related Diseases conference is a strategic gathering of numerous companies and investors, allowing entities to share current discoveries in the aging field while collaborating with those interested in funding such research. This networking opportunity will return to New York City in 2020.